Gabriel Pardo to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Gabriel Pardo has written about Randomized Controlled Trials as Topic.
Connection Strength
0.053
-
Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2026 Jan; 105:106886.
Score: 0.053